Biodegradable nanoparticles for direct or two-step tumor immunotargeting

Bioconjugate Chemistry

Volumn 17, Issue 1, 2006, Pages 139-145

  Nobs, Leila ^a   Buchegger, Franz ^b   Gurny, Robert ^a   Allémann, Eric ^a,c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Bracco Suisse SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CYTOLOGY; DISEASES; FLOW CYTOMETRY; FLUORESCENCE; MONOCLONAL ANTIBODIES; ONCOLOGY; TUMORS;

BIODEGRADABLE NANOPARTICLE; CANCER CELL TARGETING; DAUDI CELLS; IMMUNOTARGETING; IN-VITRO; LYMPHOMA CELLS; NEUTRAVIDIN; OVARIAN CANCERS; POLY LACTIC ACID; RHODAMINE;

NANOPARTICLES;

IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NANOPARTICLE; POLYLACTIC ACID; RITUXIMAB; TRASTUZUMAB;

ANALYTIC METHOD; ANTIGEN EXPRESSION; ARTICLE; BIODEGRADABILITY; BIOTINYLATION; CANCER CELL; COVALENT BOND; CROSS LINKING; DAUDI CELL; FLOW CYTOMETRY; GENE TARGETING; HUMAN; HUMAN CELL; LYMPHOMA CELL; OVARY CANCER; TARGET CELL; TUMOR IMMUNITY;

EID: 31544454201     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc050137k     Document Type: Article

References (38)

1. Satchi-Fainaro, R., Puder, M., Davies, J. W., Tran, H. T., Sampson, D. A., Greene, A. K., Corfas, G., and Folkman, J. (2004) Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 10, 255-261.
2. Crosasso, P., Ceruti, M., Brusa, P., Arpicco, S., Dosio, F., and Cattel, L. (2000) Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J. Controlled Release 63, 19-30.
3. Martin, F. J. (1998) Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin). Medical Applications of Liposomes (Lasic, D. D., and Papahadjopoulos, D., Eds.) pp 635-688, Elsevier Science BV, New York.
4. Greish, K., Sawa, T., Fang, J., Akaike, T., and Maeda, H. (2004) SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. J. Controlled Release 97, 219-230.
5. Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio, K., Matsumura, Y., and Kataoka, K. (2003) Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 63, 8977-8983.
6. Allémann, E., Rousseau, J., Brasseur, N., Kudrevich, S. V., Lewis, K., and Van Lier, J. E. (1996) Photodynamic therapy of tumours with hexadecafluoro zinc phthalocynine formulated in PEG-coated poly(lactic acid) nanoparticles. Int. J. Cancer 66, 821-824.
7. Verdun, C., Brasseur, F., Vranckx, H., Couvreur, P., and Roland, M. (1990) Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother. Pharmacol. 26, 13-18.
8. Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., and Rudzinski, W. E. (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J. Controlled Release 70, 1-20.
9. Sakhalkar, H. S., Dalal, M. K., Salem, A. K., Ansari, R., Fu, J., Kiani, M. F., Kurjiaka, D. T., Hanes, J., Shakesheff, K. M., and Goetz, D. J. (2003) Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 100, 15895-15900.
10. Leroux, J.-C., Allémann, E., De Jaeghere, F., Doelker, E., and Gurny, R. (1996) Biodegradable nanoparttcles-from sustained release formulations to improved site specific drug delivery. J. Controlled Release 39, 339-350.
11. Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., and Langer, R. (1994) Biodegradable long-circulating polymeric nanospheres. Science 263, 1600-1603.
12. Allémann, E., Brasseur, N., Benrezzak, O., Rousseau, J., Kudrevich, S. V., Boyle, R. W., Leroux, J. C., Gurny, R., and Van Lier, J. E. (1995) PEG-coated poly(lactic acid) nanoparticles for the delivery of hexadecafluoro zinc phthalocyanine to EMT-6 mouse mammary tumours. J. Pharm. Pharmacol. 47, 382-387.
13. Mamot, C., Drummond, D. C., Greiser, U., Hong, K., Kirpotin, D. B., Marks, J. D., and Park, J. W. (2003) Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery. Cancer Res. 63, 3154-3161.
14. Forssen, E., and Willis, M. (1998) Ligand-targeted liposomes. Adv. Drug Delivery Rev. 29, 249-271.
15. Goodwin, D. A., and Meares, C. F. (2001) Advances in pretargeting biotechnology. Biotechnol. Adv. 19, 435-450.
16. Sharkey, R. M., McBride, W. J., Karacay, H., Chang, K., Griffiths, G. L., Hansen, H. J., and Goldenberg, D. M. (2003) A universal pretargeting systems for cancer detection and therapy using bispecific antibody. Cancer Res. 63, 354-363.
17. Green, N. M. (1968) Spectrophotomertic determination of avidin and biotin. Methods Enzymol. 18, 418-424.
18. De Jaeghere, F., Allémann, E., Feijen, J., Kissel, T., Doelker, E., and Gurny, R. (2000) Freeze-drying and lyopreservation of diblock and triblock poly(lactic acid)-poly(ethylene oxide) (PLA-PEO) copolymer nanoparticles. Pharm. Dev. Technol. 5, 473-483.
19. Nobs, L., Buchegger, F., Gurny, R., and Allémann, E. (2003) Surface modification of poly(lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods. Int. J. Pharm. 250, 327-337.
20. Nobs, L., Buchegger, F., Gurny, R., and Allémann, E. (2004) Poly-(lactic acid) nanoparticles labled with biologically active NeutrAvidin for active targeting. Eur. J. Pharm. Biopharm. 58, 483-490.
21. Nguyen, C. A., Allemann, E., Schwach, G., Doelker, E., and Gurny, R. (2003) Synthesis of a novel fluorescent poly(D,L-lactide) end-capped with 1-pyrenebutanol used for the preparation of nanoparticles. Eur. J. Pharm. Sci. 20, 217-222.
22. De Jong, M. O., Rozemuller, H., Bauman, J. G. J., and Visser, J. W. M. (1995) Biotinylation of interleukin-2 (IL-2) for flow citometric analysis of IL-2 receptor expression. J. Immunol. Methods 184, 101-112.
23. Konan, Y. N., Chevallier, J., Gurny, R., and Allemann, E. (2003) Encapsulation of p-THPP into nanoparticles: cellular uptake, sub-cellular localization and effect of serum on photodynamic activity. Photochem. Photobiol. 77, 638-644.
24. Fonseca, C., Simoes, S., and Gaspar, R. (2002) Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Controlled Release 83, 273-286.
25. Rolland, A., Bourel, D., Genetet, B., and Le Verge, R. (1987) Monoclonal antibodies covalently coupled to polymethacrylic nanoparticles: in vitro specific targeting to human T lymphocytes. Int. J. Pharm. 39, 173-180.
26. Akasaka, Y., Ueda, H., Takayama, K., Machida, Y., and Nagai, T. (1988) Preparation and evaluation of bovine serum albumin nanospheres coated with monoclonal antibodies. Drug Des. Delivery 3, 85-97.
27. Bourel, D., Rolland, A., Le Verge, R., and Genetet, B. (1988) A new immunoreagent for cell labeling CD3 monoclonal antibody covalently coupled to fluorescent polymethacrylic nanoparticles. J. Immunol. Methods 106, 161-167.
28. De Jaeghere, F., Allémann, E., Leroux, J.-C., Stevels, W., Feijen, J., Doelker, E., and Gurny, R. (1999) Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles: influence on physical stability and in vitro cell uptake. Pharm. Res. 16, 859-866.
29. Leroux, J. C., Gravel, P., Balant, L., Volet, B., Anner, B. M., Allémann, E., Doelker, E., and Gurny, R. (1994) Internalization of poly(D,L-lactic acid) nanoparticles by isolated human leukocytes and analysis of plasma proteins adsorbed onto the particles. J. Biomed. Mater. Res. 28, 411-481.
30. Allen, T. M., Brandeis, E., Hansen, C. B., Kao, G. Y., and Zalipsky, S. (1995) A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta 127, 99-108.
31. Moro, M., Pelagi, M., Fulci, G., Paganelli, G., Dellabona, P., Casorati, G., Siccardi, A. G., and Corti, A. (1997) Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor al. Cancer Res. 57, 1922-1928.
32. Goshorn, S., Sanderson, J., Axworthy, D., Lin, Y., Hylarides, M., and Schultz, J. (2001) Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy. Cancer. Biother. Radiopharm. 16, 109-123.
33. Zhang, M., Zhang, Z., Garmestani, K., Schultz, J., Axworthy, D. B., Goldman, C. K., Brechbiel, M. W., Carrasquillo, J. A., and Waldmann, T. (2003) Pretarget radiotherpy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc. Natl. Acad. Sci. U.S.A. 100, 1891-1895.
34. Paganelli, G., Bartomomei, M., Ferrari, M., Cremonesi, M., Broggi, G., Maira, G., Sturiale, C. C., Prisco, G., Gatti, M., Caliceti, P., and Chinol, M. (2001) Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer. Biother. Radiopharm. 16, 227-235.
35. Knox, S. J., Goris, M. L., Tempero, M., Weiedn, P. L., Gentner, L., Breitz, H., Adams, G. P., Axworthy, D., Gaffigan, S., Bryan, K., Fisher, D. R., Colcher, D., Horak, I, and Weiner, L. M. (2000) Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res. 6, 406-414.
36. Rusckowski, M., Fogarasi, M., Fritz, B., and Hnatowich, D. J. (1997) Effect of endogenous biotin on the applications of streptavidin and biotin in mice. Nucl. Med. Biol. 24, 263-268.
37. Sapra, P., and Allen, T. M. (2002) Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 62, 7190-7194.
38. Mavromatis, B. H., and Cheson, B. D. (2004) Novel therapies for chronic lymphocytic leukemia. Blood Rev. 18, 137-148.